Shield Therapeutics PLC (GB:STX)
LSE:STX
Want to see GB:STX full AI Analyst Report?
Top Page
Shield Therapeutics
(LSE:STX)
Select Model
Select Model
Rating:47Neutral
Price Target:
9.50 p
▼(-3.55% Downside)
Action:ReiteratedDate:04/11/26
The score is held back primarily by weak financial quality (ongoing losses, negative operating/free cash flow, and negative equity), partially offset by improving revenue/margins and moderately constructive price trend signals. Valuation is also constrained by loss-making status and lack of dividend support.
Positive Factors
Revenue Growth
Sustained high revenue growth reflects accelerating commercial uptake of Accrufer across direct and partner channels. That scale supports better absorption of fixed costs, strengthens commercial credibility, and creates a clearer path to profitability if growth and cost discipline continue.
Negative Factors
Negative Equity
Persistent negative shareholders' equity reflects cumulative losses that have eroded the capital base. This structural weakness constrains balance sheet resilience, increases the likelihood of future dilution or restructurings, and can limit partner, lender, or investor flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained high revenue growth reflects accelerating commercial uptake of Accrufer across direct and partner channels. That scale supports better absorption of fixed costs, strengthens commercial credibility, and creates a clearer path to profitability if growth and cost discipline continue.
Read all positive factors
Shield Therapeutics (STX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£94.56M
Dividend YieldN/A
Average Volume (3M)3.16M
Price to Earnings (P/E)―
Beta (1Y)1.57
Revenue Growth49.81%
EPS Growth52.94%
CountryUK
Employees63
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,068,418,500
10 Day Avg. Volume1,665,963
30 Day Avg. Volume3,163,002
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)-5.76
Price to Sales (P/S)1.71
P/FCF Ratio-9.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£76.39M
Shield Therapeutics Business Overview & Revenue Model
Company Description
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral th...
How the Company Makes Money
Shield Therapeutics makes money primarily by commercializing Accrufer (ferric maltol). Revenue is generated through product sales in markets where the company sells directly and through collaboration/licensing arrangements in markets where commerc...
Shield Therapeutics Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
27
Negative
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 50.74M | 25.18M | 13.09M | 5.50M | 1.52M |
| Gross Profit | 22.38M | 10.57M | 4.03M | 2.00M | 539.00K |
| EBITDA | -10.30M | -16.58M | -30.29M | -46.07M | -17.69M |
| Net Income | -18.03M | -21.27M | -33.29M | -40.44M | -19.34M |
Balance Sheet | |||||
| Total Assets | 65.24M | 45.90M | 48.80M | 22.07M | 44.41M |
| Cash, Cash Equivalents and Short-Term Investments | 11.63M | 5.61M | 13.95M | 2.82M | 12.12M |
| Total Debt | 30.15M | 21.06M | 20.41M | 6.10M | 156.00K |
| Total Liabilities | 80.32M | 46.95M | 26.49M | 16.65M | 3.38M |
| Stockholders Equity | -15.08M | -1.05M | 11.79M | 5.43M | 40.69M |
Cash Flow | |||||
| Free Cash Flow | -8.83M | -7.03M | -40.07M | -20.14M | -18.80M |
| Operating Cash Flow | -8.81M | -7.01M | -37.13M | -18.25M | -16.74M |
| Investing Cash Flow | -306.29K | -1.89M | -2.43M | -1.70M | -2.05M |
| Financing Cash Flow | 13.75M | 4.21M | 49.66M | 7.71M | 27.58M |
Shield Therapeutics Technical Analysis
Positive
9.85
Price Trends
9.13
Positive
9.86
Negative
8.12
Positive
Market Momentum
0.13
Negative
57.65
Neutral
74.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:STX, the sentiment is Positive. The current price of 9.85 is above the 20-day moving average (MA) of 8.56, above the 50-day MA of 9.13, and above the 200-day MA of 8.12, indicating a bullish trend. The MACD of 0.13 indicates Negative momentum. The RSI at 57.65 is Neutral, neither overbought nor oversold. The STOCH value of 74.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:STX.
Shield Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | £74.92M | 2.80 | 7.82% | ― | ― | ― | |
59 Neutral | £2.98B | 11.21 | 15.83% | 4.16% | 3.84% | 8.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £94.56M | -4.82 | 206.44% | ― | 49.81% | 52.94% | |
45 Neutral | £690.25M | -7.21 | 409.00% | ― | 2.94% | -32.00% |
* Healthcare Sector Average
GB:STX
Shield Therapeutics
8.85
6.50
276.60%
GB:AGY
Allergy Therapeutics
10.30
3.40
49.28%
GB:HIK
Hikma Pharmaceuticals
1,397.00
-481.21
-25.62%
GB:VLG
Venture Life
58.60
17.60
42.93%
Shield Therapeutics Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingShareholder Meetings
Shield Therapeutics Hits Record ACCRUFeR Sales and Turns Cash-Flow Positive in 2025
Positive
Apr 9, 2026
Shield Therapeutics reported its strongest year to date in 2025, driven by a 56% increase in U.S. ACCRUFeR net revenue to about $46 million, making the drug the number one branded prescription oral iron in the U.S. market. Group net revenues and o...
Business Operations and StrategyProduct-Related Announcements
Shield Therapeutics Gains Pediatric Boost as Ferric Maltol Data Published in Leading Journal
Positive
Apr 1, 2026
Shield Therapeutics has highlighted the growing clinical profile of its flagship ferric maltol product after an independent, peer-reviewed report on ACCRUFeR/FeRACCRU was published in the journal Pediatric Drugs. The paper reviews the recent U.S. ...
Business Operations and StrategyRegulatory Filings and Compliance
Shield Therapeutics updates share capital and underscores global iron deficiency franchise
Positive
Mar 31, 2026
Shield Therapeutics has confirmed that its issued share capital comprises 1,068,418,471 ordinary shares with equal voting rights and no shares held in treasury. This updated share count provides investors with the reference figure needed to assess...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Shield Therapeutics gains EMA backing to extend FeRACCRU use to adolescents
Positive
Mar 31, 2026
Shield Therapeutics has secured a key regulatory win as the European Medicines Agency’s committee backed extending the indication for FeRACCRU to include adolescents, broadening its use for iron deficiency treatment in patients aged 12 and o...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Shield Therapeutics Advances ACCRUFeR Into China With NMPA Filing Acceptance
Positive
Mar 3, 2026
Shield Therapeutics said China’s National Medical Products Administration has accepted a marketing authorisation application for its ferric maltol product ACCRUFeR, filed by local partner Beijing Aosaikang Pharmaceutical. The submission, bac...
Business Operations and StrategyRegulatory Filings and Compliance
Shield Therapeutics Updates Voting Rights as Iron Drug Expansion Continues
Positive
Feb 27, 2026
Shield Therapeutics plc, a London-listed specialty pharmaceutical company, focuses on iron deficiency treatment through its innovative oral iron therapy ACCRUFeR/FeRACCRU, marketed globally via a network of regional partners. With FDA approval, br...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Shield Therapeutics Wins Extra U.S. FDA Exclusivity for ACCRUFeR Pediatric Use
Positive
Feb 9, 2026
Shield Therapeutics has secured an additional three years of U.S. FDA data exclusivity for its oral iron therapy ACCRUFeR, extending protection to 19 December 2028 on top of patent coverage into the mid-2030s. The extension follows a new clinical ...
Regulatory Filings and Compliance
Shield Therapeutics Updates Market on Total Voting Rights and Share Capital
Neutral
Jan 30, 2026
Shield Therapeutics has announced that its issued share capital now comprises 1,067,997,016 ordinary shares of 1.5p each, all carrying equal voting rights and with no shares held in treasury. This updated total voting rights figure provides the ne...
Business Operations and StrategyProduct-Related Announcements
Shield Therapeutics Secures $7.9m China Milestone as ACCRUFeR® Nears NMPA Filing
Positive
Jan 30, 2026
Shield Therapeutics has updated the terms of its licensing agreement with Beijing Aosaikang Pharmaceutical for ACCRUFeR® in China, with ASK now expected to file for marketing authorisation with China’s NMPA in the first quarter of 2026,...
Business Operations and StrategyFinancial Disclosures
Shield Therapeutics Hits Q4 Cash Flow Positivity as ACCRUFeR Sales Jump 56% in 2025
Positive
Jan 21, 2026
Shield Therapeutics reported unaudited 2025 revenues of about $50 million, driven largely by a 56% surge in U.S. ACCRUFeR sales to roughly $46 million, underpinned by a 21% increase in average net selling price and a 33% rise in total prescription...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.